Page 119 - 《中国药科大学学报》2026年第2期

第 57 卷第 2 期 孙嘉荣，等：小分子化合物 Lyb24 与二氢乳清酸脱氢酶 PyrD 的相互作用研究 245

得进一步研究。值得注意的是，上述在铜绿假单胞 es[J]. Biochemistry, 2025, 64(11): 2353-2363.
菌 中 的 研 究 结 果 表 明 ， PyrD 抑 制 剂 NDGA 和 [8] Del Arco J, Acosta J, Fernández-Lucas J. Biotechnological ap-
plications of purine and pyrimidine deaminases[J]. Biotechnol
CHX 同样展现出不具有抗菌活性，但可显著增强现 Adv, 2024, 77: 108473.
有抗生素效果的现象。上述结果提示，PyrD 抑制剂 [9] Snega Priya P, Meenatchi R, Pasupuleti M, et al. Harnessing
cyclic di-GMP signaling: a strategic approach to combat bacte-
在作为抗生素增效剂方面的应用潜能，也值得进一
rial biofilm-associated chronic infections[J]. Curr Microbiol,
步探讨。 2025, 82(3): 118.
总之，本研究明确了小分子化合物 Lyb24 抑 [10] Buckel W, Ermler U, Vonck J, et al. The RNF/NQR redox
pumps: a versatile system for energy transduction in bacteria
制 PyrD 的药理学活性，为下一步开展的结构改造
and Archaea[J]. Appl Microbiol Biotechnol, 2025, 109(1): 148.
提供了数据支持，对于开发新型的以 PyrD 为靶标 [11] Zhang ZR, Das C. Insights into mechanisms of ubiquitin ADP-
的新型抗生素开发具有重要的意义。 ribosylation reversal[J]. Biochem Soc Trans, 2024, 52(6): 2525-
2537.
[12] Akhtar AA, Turner DP. The role of bacterial ATP-binding cas-
sette (ABC) transporters in pathogenesis and virulence: Thera-
References
peutic and vaccine potential[J]. Microb Pathog, 2022, 171:
[1] Li YY, Yang X, Chen XH, et al. Research progress on resis-
105734.
tance mechanisms and therapy strategies of carbapenem resis-
[13] Agarwal AA, Georgiades JD, Dranow DM, et al. Crystal struc-
tant Klebsiella pneumonia[J]. J Mod Lab Med (现代检验医学
ture of dihydroorotate dehydrogenase from Helicobacter pylori
杂志), 2023, 38(6): 191-199.
with bound flavin mononucleotide[J]. Acta Crystallogr F Struct
[2] Chen QQ, Zhan HC, Mo JD, et al. Study on the resistance and
Biol Commun, 2025, 81(Pt 3): 108-117.
risk factors of multidrug-resistant Klebsiella pneumoniae in
[14] Rani M, Devi J, Kumar B, et al. Unveiling anti-malarial, antimi-
ventilator-associated pneumonia[J]. J Guangdong Med Univ (广
crobial, antioxidant efficiency and molecular docking study of
东医科大学学报), 2024, 42(3): 285-288.
synthesized transition metal complexes derived from hetero-
[3] Jin SS, Wang WQ, Jiang YH, et al. A comprehensive overview
cyclic schiff base ligands[J]. Chem Asian J, 2024, 19(19):
of Klebsiella pneumoniae: resistance dynamics, clinical mani-
e202400676.
festations, and therapeutic options[J]. Infect Drug Resist, 2025,
[15] Higashimura N, Hamada A, Ohara T, et al. The target site of the
18: 1611-1628.
novel fungicide quinofumelin, Pyricularia oryzae class II dihy-
[4] CHINET. CHINET 2024 annual surveillance report on bacteri-
droorotate dehydrogenase[J]. J Pestic Sci, 2022, 47(4): 190-196.
al resistance[EB/OL]. (2025-03-15) [2025-10-08]. https://www. [16] van Rhijn N, Storer ISR, Birch M, et al. Aspergillus fumigatus
chinets.com/Data/GermYear. strains that evolve resistance to the agrochemical fungicide
[5] Sati H, Carrara E, Savoldi A, et al. The WHO bacterial priority ipflufenoquin in vitro are also resistant to olorofim[J]. Nat Mi-
pathogens list 2024: a priori tisation study to guide research, de- crobiol, 2024, 9(1): 29-34.
velopment, and public health strategies against antimicrobial re- [17] Vanbiervliet Y, Van Nieuwenhuyse T, Aerts R, et al. Review of
sistance[J]. Lancet Infect Dis, 2025, 25(9): 1033-1043. the novel antifungal drug olorofim (F901318)[J]. BMC Infect
[6] Hu CX, Zhang JY, Cui RQ, et al. The enhancement effect of Dis, 2024, 24(1): 1256.
small molecule Lyb24 reveals AzoR as a novel target of [18] Overton EN, Zhang YF, Ngecu W, et al. Chemical synthetic
polymyxin B[J]. Biomed Pharmacother, 2023, 169: 115856. lethality screens identify selective drug combinations against
[7] Smith CO, Moran GR. Not once, not twice, but thrice: structure Pseudomonas aeruginosa[J]. ACS Chem Biol, 2025, 20(5):
and catalytic mechanisms of the dihydroorotate dehydrogenas- 1077-1086.